Free Trial

Structure Therapeutics (NASDAQ:GPCR) Shares Gap Up - What's Next?

Structure Therapeutics logo with Medical background
Remove Ads

Structure Therapeutics Inc. (NASDAQ:GPCR - Get Free Report)'s stock price gapped up prior to trading on Wednesday . The stock had previously closed at $20.53, but opened at $22.26. Structure Therapeutics shares last traded at $22.29, with a volume of 147,225 shares changing hands.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on GPCR. HC Wainwright reissued a "buy" rating and issued a $80.00 price target on shares of Structure Therapeutics in a report on Thursday, December 19th. William Blair started coverage on shares of Structure Therapeutics in a report on Friday, February 28th. They set an "outperform" rating on the stock. JMP Securities reissued a "market outperform" rating and set a $91.00 target price on shares of Structure Therapeutics in a research note on Wednesday, December 18th. Finally, Stifel Nicolaus began coverage on Structure Therapeutics in a report on Wednesday, January 8th. They issued a "buy" rating and a $50.00 price objective on the stock. Eight research analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $81.29.

Read Our Latest Stock Report on GPCR

Structure Therapeutics Stock Performance

The company's 50-day moving average price is $25.31 and its 200 day moving average price is $32.33. The stock has a market cap of $1.21 billion, a PE ratio of -28.45 and a beta of -2.35.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last announced its earnings results on Thursday, February 27th. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.01. As a group, equities research analysts predict that Structure Therapeutics Inc. will post -0.82 earnings per share for the current fiscal year.

Remove Ads

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the company. ANTIPODES PARTNERS Ltd raised its holdings in shares of Structure Therapeutics by 115.0% in the 4th quarter. ANTIPODES PARTNERS Ltd now owns 1,034 shares of the company's stock valued at $28,000 after buying an additional 553 shares during the period. GAMMA Investing LLC lifted its stake in Structure Therapeutics by 4,155.6% during the 4th quarter. GAMMA Investing LLC now owns 1,149 shares of the company's stock worth $31,000 after acquiring an additional 1,122 shares in the last quarter. GF Fund Management CO. LTD. acquired a new position in Structure Therapeutics during the 4th quarter worth about $34,000. FNY Investment Advisers LLC acquired a new position in Structure Therapeutics during the 4th quarter worth about $40,000. Finally, Assetmark Inc. lifted its stake in Structure Therapeutics by 120.0% during the 3rd quarter. Assetmark Inc. now owns 1,318 shares of the company's stock worth $58,000 after acquiring an additional 719 shares in the last quarter. 91.78% of the stock is currently owned by institutional investors and hedge funds.

Structure Therapeutics Company Profile

(Get Free Report)

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.

Read More

Should You Invest $1,000 in Structure Therapeutics Right Now?

Before you consider Structure Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Structure Therapeutics wasn't on the list.

While Structure Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report
Like this article? Share it with a colleague.
Remove Ads

Featured Articles and Offers

Recent Videos

7 Flying Car Stocks to Buy Before the Sector Really Takes Off
Institutions Are Dumping These 3 Stocks—Should You?
Will Tesla’s Robot Future Save Its Falling Stock?

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines

Remove Ads